Phase IIIEnrolling

Dupilumab in Moderate-to-Severe Atopic Dermatitis in UAE Adolescents

Sanofi Genzyme UAE·NCT05445678·Atopic Dermatitis

Duration

12 months

Cost

Free to Patients

Phase

Phase III

Closes

Jul 2025

About This Trial

Evaluating dupilumab safety and efficacy in UAE adolescents aged 12-17 with moderate-to-severe atopic dermatitis.

Dubai, UAE

Abu Dhabi, UAE

Condition focus: Atopic Dermatitis

Available in: UAE

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Only 40 spots remaining

Apply soon to secure your place.

Trial Summary

NCT NumberNCT05445678

SponsorSanofi Genzyme UAE

PhasePhase III

Duration12 months

ClosesJul 2025

ConditionAtopic Dermatitis